Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

88 results
Display

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial

Lim SH, Yun J, Lee MY, Kim HJ, Kim KH, Kim SH, Lee SC, Bae SB, Kim CK, Lee N, Lee KT, Park SK, Lee YN, Moon JH

Purpose: Erlotinib has been the only targeted agent to show significantly improved outcomes in pancreatic adenocarcinoma when combined with gemcitabine. We aimed to evaluate whether the addition of oxaliplatin to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells

Boonsri B, Yacqub-Usman K, Thintharua P, Myint KZ, Sae-Lao T, Collier P, Suriyonplengsaeng C, Larbcharoensub N, Balasubramanian B, Venkatraman S, Egbuniwe IU, Gomez D, Mukherjee A, Kumkate S, Janvilisri T, Zaitoun AM, Kuakpaetoon T, Tohtong R, Grabowska AM, Bates DO, Wongprasert K

Purpose The potential of members of the epidermal growth factor receptor (ErbB) family as drug targets in cholangiocarcinoma (CCA) has not been extensively addressed. Although phase III clinical trials showed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
KAT8/MOF-Mediated Anti-Cancer Mechanism of Gemcitabine in Human Bladder Cancer Cells

Zhu H, Wang Y, Wei T, Zhao X, Li F, Li Y, Wang F, Cai Y, Jin J

Histone acetylation is a well-characterized epigenetic modification controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs). Imbalanced histone acetylation has been observed in many primary cancers. Therefore, efforts have been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?

Hwang DW, Shin E, Cho JY, Han HS, Yoon YS

Backgrounds/Aims: Gemcitabine is still one of adjuvant options in chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC). Integral membrane transporter protein and intracellular enzymes including human equilibrative nucleoside transporter 1 (hENT1),...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Radiation Recall Myositis during Gemcitabine Chemotherapy

Park JH, Kim Y, Yeo SM, Hwang JH

Radiation recall is an uncommon phenomenon in which administration of a chemotherapy or another systemic agent induces an acute inflammatory reaction in previously irradiated tissues, often weeks to years after...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Lee K, Bang K, Yoo C, Hwang I, Jeong JH, Chang HM, Oh D, Song TJ, Park DH, Lee SS, Lee SK, Kim MH, Park Jh, Kim Kp, Ryoo BY

Purpose Since the introduction of nab-paclitaxel plus gemcitabine (nab-P+GEM) as first-line (1L) treatment for metastatic pancreatic adenocarcinoma (mPDAC), optimal second-line (2L) chemotherapy after progression is unclear. We assessed clinical outcomes of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin

Hyung J, Kim B, Yoo C, Kim KP, Jeong JH, Chang HM, Ryoo BY

PURPOSE: Gemcitabine plus cisplatin (GemCis) is the standard first-line chemotherapy for patients with advanced biliary tract cancer (BTC). In ABC-02 study, the BTC patients received up to 6-8 cycles of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Extraordinary Response of Metastatic Pancreatic Cancer to Chemotherapy

Shin DW, Kim J, Lee JC, Kim J, Hwang JH

A 58-year-old woman presented with right flank and back pain for one month. After undergoing an abdominal computed tomography (CT), she was referred to our hospital. The abdominal CT showed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Antiviral Activity of Gemcitabine Against Echovirus 30 Infection in Vitro

Choi HJ, Song JH, Yoon K

Echovirus 30 is one of the major causes of meningitis in children and adults. The purpose of our current study was to investigate whether selected antiviral drugs could provide antiviral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment of advanced stage cholangiocarcinoma: Systemic therapy may be the starting step for radical surgery

Baik H, Seo SH, Kim KH, Choi MY, Park YH, Choi CS

Cholangiocarcinoma is the most common biliary malignancy and the second most common hepatic malignancy following hepatocellular carcinoma. It can be classified anatomically as intrahepatic cholangiocarcinoma (iCCA), perihilar CCA, or distal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer

You MS, Ryu JK, Choi YH, Choi JH, Huh G, Paik WH, Lee SH, Kim YT

BACKGROUND/AIMS: The combination of nab-paclitaxel and gemcitabine (nab-P/Gem) is widely used for treating meta-static pancreatic cancer (MPC). We aimed to evaluate the therapeutic outcomes and prognostic role of treatment-related peripheral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study

Choi Y, Yun MS, Lim SH, Lee J, Ahn JH, Kim YJ, Park KH, Park YS, Lim HY, An H, Suh DC, Kim YH

PURPOSE: This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gemcitabine-induced myositis in a diabetes mellitus patient on hemodialysis

Chun JY, Lee JM, Ahn DW, Chai JW, Kim YA, Shin K

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
KRAS G₁₂C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer

Park S, Kim JY, Lee SH, Suh B, Keam B, Kim TM, Kim DW, Heo DS

BACKGROUND/AIMS: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer

Jeon YW, Kim TH, Youn HJ, Han S, Jung Y, Gwak G, Park YS, Kim JS, Suh YJ

PURPOSE: The current multicenter phase II study was conducted to evaluate the efficacy and safety of the combination of docetaxel and gemcitabine as neoadjuvant chemotherapy (NAC) for locally advanced breast...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
α, γ-Mangostins Induce Autophagy and Show Synergistic Effect with Gemcitabine in Pancreatic Cancer Cell Lines

Kim M, Chin YW, Lee EJ

Pancreatic cancer is one of the most lethal and aggressive cancers in the world. However, no effective treatment is currently available for pancreatic cancer. The objective of this study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study

Woo SM, Kim MK, Joo J, Yoon KA, Park B, Park SJ, Han SS, Lee JH, Hong EK, Kim YH, Moon H, Kong SY, Kim TH, Lee WJ

PURPOSE: This study assessed the feasibility and compliance of induction chemotherapy with gemcitabine and cisplatin followed by simultaneous integrated boost–intensity modulated radiotherapy (SIB-IMRT) with concurrent gemcitabine in patients with locally...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M

PURPOSE: The phase 3 randomized SQUIRE study revealed significantly longer overall survival (OS) and progression-free survival (PFS) for necitumumab plus gemcitabine and cisplatin (neci+GC) than for gemcitabine and cisplatin alone...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical implications of APEX1 and Jagged1 as chemoresistance factors in biliary tract cancer

Kim HB, Cho WJ, Choi NG, Kim SS, Park JH, Lee HJ, Park SG

PURPOSE: Biliary cancer is a highly malignant neoplasm with poor prognosis and most patients need to undergo palliative chemotherapy, however major clinical problem associated with the use of chemotherapy is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer

Moon DC, Lee HS, Lee YI, Chung MJ, Park JY, Park SW, Song SY, Chung JB, Bang S

PURPOSE: Erlotinib-gemcitabine combined chemotherapy is considered as the standard treatment for unresectable pancreatic cancer. This study aimed to determine the clinical factors associated with response to this treatment. MATERIALS AND METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr